Adjuvant Capital
Adjuvant Capital is a life sciences investment firm focused on global health.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Adjuvant Capital Information
Geographic Data
Address: -
City: New York
State: NY
Zip: 11217
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$300M
Social
Twitter
Linkedin
Crunchbase
Metrics
6,896,432Website Global Rank
684Website Monthly Traffic
Twitter Followers
Description
Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2021 | 54gene | Series B | 0 |
| 10/2022 | 54gene | Convertible Note | 50M |
| 5/2020 | ChromaCode | Series C | 10M |
| 9/2019 | InDevR | Series A | 7M |
| 2/2022 | Memo Therapeutics | Series B | 0 |
| 1/2022 | Curevo | Series A | 0 |
| 10/2020 | Evofem Biosciences | Post-IPO Debt | 25M |
| 1/2023 | InDevR | Series B | 9M |
| 11/2019 | AN2 Therapeutics | Series A | 0 |
| 2/2021 | Excision BioTherapeutics | Series A | - |
| 5/2021 | Pulmocide | Series C | 0 |
| 9/2019 | Themis Bioscience | Series D | 44.1M |
| 7/2021 | VitriVax | Series A | - |
| 11/2022 | Curevo | Series A | 0 |
| 2/2021 | Frontier Nutrition | Series B | 6M |
| 4/2023 | Antiva Biosciences | Series E | 0 |
| 1/2020 | Codagenix | Series B | 0 |
| 2/2021 | Yisheng Biopharma | Series B | 0 |
| 12/2020 | Minervax | Series B | 57.6M |
| 12/2022 | Minervax | Series C | 0 |
| 4/2020 | 54gene | Series A | 0 |
| 10/2022 | Univercells | Series D | 0 |
| 2/2021 | Excision BioTherapeutics | Venture Round | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 12/2022 | Pulmocide | Series C | 0 |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 12/2020 | Univercells | Series C | 24.5M |
| 2/2022 | Memo Therapeutics | Series B | 0 |
| 1/2022 | Curevo | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 9/2021 | 54gene | Series B | 0 |
| 7/2021 | VitriVax | Series A | - |
| 5/2021 | Pulmocide | Series C | 0 |
| 2/2021 | Yisheng Biopharma | Series B | 0 |
| 2/2021 | Excision BioTherapeutics | Venture Round | 0 |
| 2/2021 | Frontier Nutrition | Series B | 0 |
| 2/2021 | Excision BioTherapeutics | Series A | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
